Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BY-NC-NDJTO clinical and research reports

High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L)

  • Yoshihiko Sakata1
  • Kenta Murotani2
  • Daichi Fujimoto3
  • Yukihiro Toi4
  • Toshihide Yokoyama5
  • Seigo Katakura6
  • Teppei Yamaguchi7
  • Kaoru Tanaka8
  • Satoru Miura9
  • Motohiro Tamiya10
  • Motoko Tachihara11
  • Takehito Shukuya12
9 more authors
  • Yuko Tsuchiya13
  • Yuki Sato14
  • Satoshi Ikeda15
  • Shinya Sakata16
  • Takeshi Masuda17
  • Shinnosuke Takemoto18
  • Hirotsugu Kenmotsu19
  • Isamu Okamoto20
  • Nobuyuki Yamamoto21
21 affiliations
  1. 1Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan
  2. 2Biostatistics Center, Kurume University, Fukuoka, Japan
  3. 3Department of Respiratory Medicine and Hematology, Hyogo Medical University, Hyogo, Japan
  4. 4Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan
  5. 5Department of Respiratory Medicine, Kurashiki Central Hospital, Okayama, Japan
  6. 6Department of Thoracic Oncology, Kanagawa Cancer Center, Kanagawa, Japan
  7. 7Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan
  8. 8Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan
  9. 9Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan
  10. 10Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan
  11. 11Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
  12. 12Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan
  13. 13Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan
  14. 14Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan
  15. 15Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan
  16. 16Department of Thoracic Oncology, Kansai Medical University, Osaka, Japan
  17. 17Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan
  18. 18Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  19. 19Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
  20. 20Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  21. 21Internal Medicine III, Wakayama Medical University, Wakayama, Japan
Read full textPDFCite

Related

  1. High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in
    Yoshihiko Sakata, MD, Kenta Murotani, PhD, Daichi Fujimoto, MD, PhD +18
    JTO Clinical and Research ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyDOAJPMC
  2. Clinical and molecular prognostic factors associated with outcomes of first-line osimertinib in EGFR-Mutated advanced NSCLC: a systematic review and meta-analysis.
    Yingding Ruan, Hongsheng Xue, Chuan Long +3
    BMC cancerPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCDOAJ
  3. Frailty as a Predictor of Mortality in Dialysis: A Multicenter Validation of the Clinical Frailty Scale
    Maxime Ingwiller, François Chantrel, Thierry Krummel +5
    Kidney medicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Irreparable Posterosuperior Rotator Cuff Tears Treated With InSpace Balloon With or Without Arthroscopic Subscapularis Repair: Short‐Term Clinical Outcomes in a Multicenter Retrospective Study
    Yash Sewpaul, Adam Mansour, Alexandra Makenzie +7
    Arthroscopy, sports medicine, and rehabilitationPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMC
  5. Baseline miR-10a, miR-146a, and miR-155 expression and subsequent clinical and radiological outcomes in multiple sclerosis : A retrospective observational study
    Furkan Sarıdaş, Havva Tezcan Ünlü, Gülşah Çeçener +2
    MedicinePeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{sakata2026high,
  title = {{High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L)}},
  author = {Yoshihiko Sakata and Kenta Murotani and Daichi Fujimoto and Yukihiro Toi and Toshihide Yokoyama and Seigo Katakura and Teppei Yamaguchi and Kaoru Tanaka and Satoru Miura and Motohiro Tamiya and Motoko Tachihara and Takehito Shukuya and Yuko Tsuchiya and Yuki Sato and Satoshi Ikeda and Shinya Sakata and Takeshi Masuda and Shinnosuke Takemoto and Hirotsugu Kenmotsu and Isamu Okamoto and Nobuyuki Yamamoto},
  journal = {JTO clinical and research reports},
  year = {2026},
  month = jul,
  url = {https://europepmc.org/article/PMC/PMC13720686},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L)
AU  - Yoshihiko Sakata
AU  - Kenta Murotani
AU  - Daichi Fujimoto
AU  - Yukihiro Toi
AU  - Toshihide Yokoyama
AU  - Seigo Katakura
AU  - Teppei Yamaguchi
AU  - Kaoru Tanaka
AU  - Satoru Miura
AU  - Motohiro Tamiya
AU  - Motoko Tachihara
AU  - Takehito Shukuya
AU  - Yuko Tsuchiya
AU  - Yuki Sato
AU  - Satoshi Ikeda
AU  - Shinya Sakata
AU  - Takeshi Masuda
AU  - Shinnosuke Takemoto
AU  - Hirotsugu Kenmotsu
AU  - Isamu Okamoto
AU  - Nobuyuki Yamamoto
PY  - 2026
DA  - 2026/07/24
JO  - JTO clinical and research reports
UR  - https://europepmc.org/article/PMC/PMC13720686
SN  - 2666-3643
ER  -